Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile
Authors:
- Nathalie GarçonNGNathalie Garçon
- Martine WettendorffMWMartine Wettendorff
- Marcelle Van MechelenMMMarcelle Van Mechelen
- 9 March 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 11 (5) , 667-677
Abstract
Introduction: Understanding the mode of action of adjuvants is important for the interpretation of clinical studies. Areas covered: This paper discusses how the results of GSK's clinical studies with an AS04-adjuvanted human papillomavirus (HPV) vaccine are supported by the mode of action of AS04. AS04 and antigens must be injected at the same intramuscular site together or within 24 h of each other. AS04 induces local cytokine production leading to increased recruitment of dendritic cells and monocytes and raised numbers of antigen presenting cells in the draining lymph node. The localized and transient nature of the innate immune response supports the acceptable safety profile observed in clinical studies. The readers will gain a comprehensive understanding of the mode of action of AS04 and how it relates to results of clinical studies. Expert opinion: The AS04-adjuvanted HPV vaccine has an acceptable safety profile and induces an enhanced and sustained immune response and high protection against HPV ty...Keywords
This publication has 79 references indexed in Scilit:
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Follicular Helper T Cells: Lineage and LocationImmunity, 2009
- Mechanism of action of clinically approved adjuvantsCurrent Opinion in Immunology, 2009
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccinesVaccine, 2008
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvantCellular and Molecular Life Sciences, 2008
- Vaccine Adjuvants Alter TCR-Based Selection ThresholdsImmunity, 2008
- Antigen presentation by monocytes and monocyte-derived cellsCurrent Opinion in Immunology, 2008
- Pathogen Recognition and Innate ImmunityCell, 2006
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003